Stanford neuroscientist Dr. Andrew Huberman has observed a shift in how the wellness community discusses weight loss treatments, particularly GLP-1 agonists like Ozempic and Wegovy. During a recent podcast appearance, Huberman explained the fascinating science behind GLP-1s.
These peptides were originally discovered in Gila Monsters, reptiles that only need to eat once yearly. Researchers wondered how these creatures avoided hunger for such extended periods and discovered elevated levels of GLP-1 circulating in their systems.
He stated, “These reptiles only need to eat once every year or so. A smart biologist said, ‘How come they don’t get hungry all year long?’ Turns out they have very high levels of GLP-1 circulating, isolated the peptide. We now have GLP1s as perhaps the first really effective treatment for obesity and diabetes.”
The medications show promise beyond weight management. Emerging research suggests GLP-1s may effectively reduce cravings for alcohol and sugar in people with alco hol use disorder, opening new therapeutic avenues.
However, Huberman noted a contradiction in how these medications were received. Initially, when GLP-1s were expensive brand-name prescriptions, the wellness and biohacking communities were highly critical.
Many dismissed them as shortcuts or potentially harmful interventions, despite their effectiveness at lowering body weight. Concerns about side effects dominated discussions, though Huberman acknowledged these medications can be taken safely with proper medical supervision.
The turning point came when GLP-1s became available through compounding pharmacies at significantly lower costs. Suddenly, the same wellness community that had disparaged these treatments reversed course.
“The moment that the GLP1s hit the compounding pharmacy market and it was inexpensive, it was suddenly like the wellness biohacking community was like, ‘Oh, okay. This is great. This is just like a supplement, no problem,'” Huberman observed.
This shift shows a major problem in health communication. “People are just too entrenched in the camp they’re in,” Huberman said. He believes a “league of reasonable people” exists who aren’t polarized between theories and rigid adherence to double-blind studies. These individuals represent the majority but often lack the loudest voices.
Huberman positions himself at the intersection of academic medicine and wellness culture, two communities he describes as “really like at loggerheads.” He takes criticism from both sides but maintains that valuable insights exist across the spectrum.
The professor advocates for better science communication that explains not just what people should do, but why.
“How people come to learn information strongly impacts whether and how they use that information,” he explained. When people understand mechanisms behind recommendations, they can better filter incoming health advice through rational frameworks.
